Cellectis (NASDAQ:CLLS) Releases Earnings Results, Misses Estimates By $0.16 EPS

Cellectis (NASDAQ:CLLS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16), Zacks reports. Cellectis had a negative net margin of 58.06% and a negative return on equity of 51.22%. The firm had revenue of $15.50 million for the quarter, compared to analysts’ expectations of $10.74 million.

Cellectis Price Performance

Shares of NASDAQ:CLLS opened at $3.45 on Friday. The business has a 50-day moving average of $3.86 and a two-hundred day moving average of $3.92. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.49 and a current ratio of 1.49. Cellectis has a 12 month low of $1.10 and a 12 month high of $5.48.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Clear Str upgraded Cellectis to a “strong-buy” rating in a report on Tuesday, December 23rd. Jefferies Financial Group began coverage on Cellectis in a report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cellectis presently has an average rating of “Moderate Buy” and an average price target of $6.33.

Hedge Funds Weigh In On Cellectis

Hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Cellectis by 228.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock worth $5,856,000 after purchasing an additional 3,284,409 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Cellectis in the fourth quarter valued at about $15,385,000. Citadel Advisors LLC purchased a new stake in shares of Cellectis during the 3rd quarter valued at about $633,000. Marshall Wace LLP raised its holdings in shares of Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the period. Finally, Millennium Management LLC lifted its position in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares in the last quarter. Hedge funds and other institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.